Parmax Pharma Ltd.
Snapshot View

View in App

Prices View details

39.20 +2.40 ▲6.5%

27 May 2022, 04:01:00 PM
Volume: 258

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.parmaxpharma.com
Market Cap 14.67 Cr.
Enterprise Value(EV) 21.37 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -0.31 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 28.15 Trailing Twelve Months Ending 2021-12
Book Value / Share 10.98 Trailing Twelve Months Ending 2021-12
Price to Book Value 3.57 Calculated using Price: 39.20
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.37 Cr. 3,741,300 Shares
FaceValue 10
Company Profile

Parmax Pharma was incorporated on November 02, 1994. The certificate of commencement of business was received by the company on March 10, 1995.The IPO of the company was January 30, 1996 with 5100800 shares of Rs10/-each. The promoters were earlier in manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The company then discontinued its business activities for few years due to various reasons. The company also plans to extend its activity in formulation of Tablets, Capsules, Ointments, & Injectable.

Objective

The objective of the company is to carry on business as manufacturers, producers, refiners, mixers, processors, repackers, distillers, formulators, convertors, extractors, buyers, sellers, wholesalers, retailers, distributors, suppliers, importers, extractors, or otherwise to deal in all kinds of drug and drugs used in pharmaceutical, medicinal biological immunological, contraceptive and therapeutim preparations, substance materials and articles of all classes and description whether simple compound or otherwise, and also drugs used in disinfectants, antiseptic and of cordials antibiotics tinctures lozenges syrups, capsules, tablets, tablets inject able , liquid lotions ointments, restoratives, vitamins, nonmones , ayurvedic, medicines, proprietory medicines, pharmaceutical chemicals, chemical compounds having chemical properties.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+6.52%
1 Week
+4.39%
1 Month
-3.21%
3 Month
-19.18%
6 Month
-4.97%
1 Year
-32.88%
2 Year
+8.74%
5 Year
+135.44%
10 Year

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -0.96 1.16 0.70 -0.12 -0.28 0.02 3.71 18.19 22.55
Return on Capital Employed (%) -0.74 1.01 0.88 0.28 0.18 0.81 1.96 10.19 16.25
Return on Assets (%) -0.61 0.73 0.45 -0.08 -0.12 0.00 0.43 2.11 3.45

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 4 4 4 5 5 5 5 5 6 7
Non Curr. Liab. 1 1 1 0 1 2 5 5 6 7
Curr. Liab. 0 0 0 0 2 10 10 11 11 6
Minority Int.
Equity & Liab. 5 5 5 5 8 17 20 21 23 20
Non Curr. Assets 3 3 3 3 3 6 9 10 11 11
Curr. Assets 1 2 2 2 4 9 9 9 10 8
Misc. Exp. not W/O 1 1 1 1 1 2 2 2 1
Total Assets 5 5 5 5 8 17 20 21 23 20

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 12 12 21 26 19
Other Income 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 12 12 21 26 19
Total Expenditure 0 0 0 0 0 -11 -11 -19 -23 -16
PBIDT 0 0 0 0 0 1 1 2 4 3
Interest 0 0 0 0 0
Depreciation -1 -1 -1 -2 -2
Taxation 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 1 0
Adjusted EPS 0 0 0 0 0 0 1 2 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 -1 4 1 3 4
Cash Fr. Inv. 0 -4 -3 -2 -3
Cash Fr. Finan. 0 0 0 1 1 3 0 0
Net Change 0 0 0 1 1 0 1
Cash & Cash Eqvt 0 0 0 0 0 0 1 2 2 3

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80
Public 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 23 May 2022
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Fri, 29 Apr 2022
Disclosure In Pursuance Of SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 Dated 26THNovember 2018.
We would like to inform you that our company is not falling under the category of "Large Corporate (LC)" as per the framework provided in the aforesaid Circular.
Thu, 21 Apr 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st March 2022.

Technical Scans View Details

Fri, 27 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Opening at High for 3 days Opening at High for 3 days
High Decrease 3 Months High Decrease 3 Months
High Decrease 1 Year High Decrease 1 Year

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,539.98 902.50 +0.2%
Divi's Laboratories Ltd. 93,297.61 3,514.45 +1.9%
Cipla Ltd. 77,954.36 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. 73,094.23 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. 55,313.96 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. 49,744.83 2,939.85 +1.3%
Gland Pharma Ltd. 47,677.82 2,897.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.60 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 31.51 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 30.97 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.49 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.40 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 64.02 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 39.35 2,897.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.19 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 7.95 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 3.74 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.80 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.81 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.36 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 6.66 2,897.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 0.10 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,897.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,897.00 +1.5%